Leukemia

publication venue for

Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. 2023
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. 2021
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. 2021
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. 2014
The co-receptor Neuropilin-1 enhances proliferation in inv(16) acute myeloid leukemia via VEGF signaling. 2024
JAK2^V617F impairs lymphoid differentiation in myeloproliferative neoplasms. 2024
NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia. 2024
Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity. 2024
FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia. 2024
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. 2023
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. 2023
MAPK-negative feedback regulation confers dependence to JAK2^V617F signaling.. 37. 2023
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice.. 37. 2023
KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition. 2023
BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8⁺ T cells. 2023
Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival. 2022
Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms. 2022
CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response.. 37. 2022
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma.. 37. 2022
MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis.. 36. 2021
Normal life expectancy for polycythemia vera (PV) patients is possible. 2021
Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS). 2021
Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy.. 35. 2021
Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. 2021
Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma. 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. 2021
RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators.. 35. 2021
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. 2021
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.. 35. 2021
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival.. 35. 2021
Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma.. 35. 2021
Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia.. 35. 2021
Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target.. 35. 2021
U2af1 is required for survival and function of hematopoietic stem/progenitor cells.. 35. 2021
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.. 35. 2020
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.. 34. 2020
Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin.. 35. 2020
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response.. 35. 2020
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.. 34. 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.. 35. 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.. 34. 2020
The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK^- anaplastic large cell lymphoma by regulating the DNA helicase HELLS.. 34. 2020
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.. 34. 2020
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.. 34. 2019
Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.. 34. 2019
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications.. 34. 2019
Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.. 33. 2019
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.. 33. 2019
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.. 33. 2019
Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia.. 33. 2019
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia.. 33. 2019
A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity.. 33. 2019
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.. 33. 2019
Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.. 33. 2019
Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.. 33. 2018
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.. 33. 2018
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.. 32. 2018
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.. 33. 2018
Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.. 32. 2018
Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma.. 32. 2017
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.. 32. 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.. 32. 2017
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.. 31. 2017
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.. 31. 2017
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.. 31. 2016
Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22.. 31. 2016
Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.. 31. 2016
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.. 31. 2016
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.. 31. 2016
Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.. 31. 2016
Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.. 31. 2016
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.. 30. 2016
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.. 31. 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.. 31. 2016
Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias.. 31. 2016
DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.. 30. 2016
Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling.. 30. 2016
Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.. 30. 2016
Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells.. 30. 2015
EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis.. 30. 2015
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.. 30. 2015
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.. 30. 2015
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.. 29. 2015
FoxO1-dependent induction of acute myeloid leukemia by osteoblasts in mice.. 30. 2015
Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.. 29. 2015
Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.. 29. 2015
IL10 receptor is a novel therapeutic target in DLBCLs.. 29. 2015
Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.. 29. 2015
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. 29. 2014
Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells.. 29. 2014
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.. 29. 2014
IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.. 29. 2014
Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia.. 28. 2014
Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.. 28. 2014
Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway.. 28. 2014
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.. 28. 2013
Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia.. 28. 2013
Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy.. 28. 2013
Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas.. 28. 2013
Toll-like receptor alterations in myelodysplastic syndrome.. 27. 2013
AKT is a therapeutic target in myeloproliferative neoplasms.. 27. 2013
Physiologic corticosterone oscillations regulate murine hematopoietic stem/progenitor cell proliferation and CXCL12 expression by bone marrow stromal progenitors.. 27. 2013
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.. 27. 2013
Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells.. 27. 2013
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.. 27. 2013
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.. 27. 2013
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.. 27. 2012
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.. 27. 2012
PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.. 27. 2012
MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.. 27. 2012
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.. 27. 2012
miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation.. 27. 2012
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.. 27. 2012
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.. 26. 2012
Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.. 26. 2012
Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent.. 26. 2012
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.. 26. 2012
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.. 26. 2011
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity.. 26. 2011
The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia.. 25. 2011
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.. 25. 2010
PHF6 mutations in adult acute myeloid leukemia.. 25. 2010
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.. 24. 2010
A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.. 23. 2009
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.. 23. 2009
Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells.. 23. 2009
Monoclonal antibodies against IREM-1: potential for targeted therapy of AML.. 23. 2009
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.. 23. 2009
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.. 23. 2009
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.. 23. 2009
Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy.. 23. 2009
Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.. 23. 2008
Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.. 23. 2008
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.. 22. 2008
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.. 22. 2008
Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.. 22. 2008
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.. 22. 2008
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.. 22. 2008
Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.. 22. 2008
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.. 22. 2007
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.. 22. 2007
Genetically identical twin transplantation for chronic lymphocytic leukemia.. 21. 2007
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.. 21. 2007
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements.. 21. 2007
The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.. 21. 2007
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.. 21. 2007
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma.. 21. 2006
Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.. 20. 2006
Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2.. 20. 2006
Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells.. 20. 2006
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.. 20. 2006
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.. 20. 2006
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.. 20. 2006
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.. 19. 2005
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).. 19. 2005
Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.. 18. 2004
Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group.. 18. 2004
Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.. 18. 2004
Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha.. 17. 2003
A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia.. 17. 2003
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.. 17. 2003
Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.. 17. 2003
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.. 17. 2003
Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones.. 16. 2002
Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo.. 16. 2002
Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.. 16. 2002
Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission.. 15. 2001
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells.. 14. 2000
A novel in vitro model of early human adult B lymphopoiesis that allows proliferation of pro-B cells and differentiation to mature B lymphocytes.. 14. 2000
Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.. 14. 2000
Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4.. 14. 2000
Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid.. 13. 1999
Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis.. 13. 1999
A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia.. 12. 1998
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.. 11. 1997
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission.. 11. 1997
Rapid induction of B-cell lymphomas by avian leukosis virus.. 11 Suppl 3. 1997
Decitabine studies in chronic and acute myelogenous leukemia.. 11 Suppl 1. 1997
Studies of decitabine with allogeneic progenitor cell transplantation.. 11 Suppl 1. 1997
c-kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells.. 10. 1996
Establishment of AIDS-related lymphoma cell lines from lymphomatous effusions.. 10. 1996
Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice.. 10. 1996
c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia.. 10. 1996
Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.. 10. 1996
A pilot study of the biologic and therapeutic effects of granulocyte colony-stimulating factor (filgrastim) in patients with acute myelogenous leukemia.. 9. 1995
Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.. 9. 1995
Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia.. 9. 1995
Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B.. 9. 1995
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.. 9. 1995
Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia.. 8. 1994
Comparative activity of tamoxifen and N-desmethyltamoxifen in human multidrug resistant leukemia cell lines.. 8. 1994
Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience.. 8. 1994
Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs.. 8. 1994
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.. 8. 1994
A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations.. 8. 1994
Phase I-II trial of high dose Ara-C, carboplatinum, etoposide and steroids in patients with refractory or relapsed lymphomas.. 8. 1994
In vitro establishment of AIDS-related lymphoma cell lines: phenotypic characterization, oncogene and tumor suppressor gene lesions, and heterogeneity in Epstein-Barr virus infection.. 7. 1993
Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease.. 7. 1993
Interleukin-4 priming enhances a target for human complement-mediated cytotoxicity of CLL.. 7. 1993
Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia.. 7. 1993
Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.. 6. 1992
Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.. 6. 1992
Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia.. 5. 1991
Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia.. 5. 1991
Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination.. 5. 1991
Diffuse large cell lymphoma. Prognostic factors with treatment.. 5 Suppl 1. 1991
Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma.. 4. 1990
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.. 4. 1990
Establishment and characterization of two human myeloma cell lines secreting kappa light chains.. 3. 1989
Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia.. 3. 1989
Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia.. 3. 1989
Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195.. 3. 1989
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.. 3. 1989
The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia.. 2. 1988
Patterns of T cell receptor gamma gene rearrangement and expression in B and T lymphoid malignancies.. 2. 1988
Juvenile chronic myeloid leukemia: therapeutic insights.. 1. 1987
Diagnosis and monitoring in patients with hairy cell leukemia using the monoclonal antibody anti-HC2.. 1. 1987
Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.. 1. 1987
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.. 34. 2019
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.. 33. 2019
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.. 33. 2019
A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies.. 32. 2017
Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.. 31. 2016
The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.. 30. 2016
In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche.. 30. 2015
Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia.. 30. 2015
A unique aptamer-drug conjugate for targeted therapy of multiple myeloma.. 30. 2015
Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.. 29. 2015
Biological properties of ligand-dependent activation of the MET receptor kinase in acute myeloid leukemia.. 29. 2014
The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma.. 29. 2014
Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis.. 29. 2014
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.. 28. 2014
Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial.. 28. 2013
Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies.. 28. 2013
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.. 27. 2013
Defined, serum-free conditions for in vitro culture of primary human T-ALL blasts.. 27. 2012
Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma.. 26. 2011
The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration.. 24. 2010
Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines.. 24. 2009
Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis.. 23. 2009
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.. 23. 2009
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.. 22. 2008
Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation.. 22. 2008
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.. 22. 2007
Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation.. 21. 2007
A novel family of slitrk genes is expressed on hematopoietic stem cells and leukemias.. 21. 2007
JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?. 20. 2006
NK-cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis.. 20. 2006
Ph-positive and -negative myeloproliferative syndromes may co-exist.. 18. 2004
Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.. 17. 2003
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma.. 17. 2003
Thalidomide therapy induces response in relapsed mantle cell lymphoma.. 17. 2003
Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera.. 17. 2003
Spotlight on acute promyelocytic leukemia: controversies and challenges.. 16. 2002
Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571.. 15. 2001
Extensive bone marrow necrosis associated with multiple myeloma.. 13. 1999
Discordant erythropoiesis in CML.. 12. 1998
Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? 2005
Tumor evolution analysis uncovered immune-escape related mutations in relapse of diffuse large B-cell lymphoma. 2024
CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition. 2023
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. 2022
Risk of disease progression in low-risk MDS is linked to distinct epigenetic subtypes. 2019
Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. 2019
Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia. 2017
Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. 2015
Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group. 2015
Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. 2012
Clinical activity of arsenic trioxide in Burkitt-like lymphoma. 2003
Chronic myeloid leukemia--some topical issues.. 21. 2007
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. 2021
Genome instability in multiple myeloma. 2020
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. 2020
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. 2017
Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. 2016
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. 2016
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). 2014
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). 2013
Clonal evolution in hematological malignancies and therapeutic implications. 2013
The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics. 2012
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. 2012
Management of treatment-emergent peripheral neuropathy in multiple myeloma. 2011
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. 2009
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. 2008
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. 2007
Predicting the effect of transcription therapy in hematologic malignancies. 2005
Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. 2003
Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. 1993
Pediatric leukemia/lymphoma with t(8;14)(q24;q11). 1992
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. 2022
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. 2018
Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. 2012
Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. 2011
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. 2003
Allogeneic and autologous transplantation for chronic lymphocytic leukemia. 2001
High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease. 1989

VIVO Weill Cornell Medical College

Leukemia Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)